O‐GlcNAcylated TAP1 Impairs Antigen Presentation and Promotes Immune Evasion in Bladder Cancer

Read full text
Authors: Jinpeng Wu, Xueting Ren, Zhen Zhai, Lu Wang, Liang Liang, Zengqi Tan, Jiazhen Zhao, Yuxuan Han, Y F Li, Feng Guan, X.C. Li
Cited by: 1
References: 18

Abstract

ABSTRACT Major histocompatibility complex class I (MHC‐I) proteins play a crucial role in immune surveillance by presenting newly synthesized antigens to CD8 + T cells on the cell surface. The downregulation of MHC‐I impairs antigen presentation and facilitates immune evasion in bladder cancer. O‐GlcNAcylation, an O‐linked N‐acetylglucosamine modification that is upregulated in various cancers, is increasingly recognized for its role in immune regulation. However, its specific role in antigen presentation remains unclear. In this study, we identified an inverse correlation between O‐GlcNAcylation levels and immune cell infiltration, specifically reducing CD8 + T cell numbers in bladder cancer. Reducing cellular O‐GlcNAcylation significantly enhanced antigen presentation efficiency. We demonstrated that O‐GlcNAcylation of antigen peptide transporter 1 (TAP1), a key transporter in the antigen presentation pathway, disrupts its interaction with MHC‐I, thereby promoting the autophagic‐lysosomal degradation of MHC‐I and impairing CD8 + T cell‐mediated cytotoxicity. Inhibiting O‐GlcNAcylation of TAP1 significantly augmented antitumor immune responses. Collectively, these findings reveal a novel mechanism by which O‐GlcNAcylation facilitates immune evasion in bladder cancer and suggest a potential therapeutic strategy for enhancing TAP/MHC‐I‐mediated antigen presentation.

Fields of Study & Subjects

Glycosylation and Glycoproteins Research Immune Cell Function and Interaction Immunotherapy and Immune Responses

Publication details

Journal / source
Advanced Science
Publisher
Wiley
Volume
13
Issue
37
Pages
e19955–e19955
Publication date
24 April 2026
Language
EN